Loading...
Market
How will Lantheus Holdings' valuation change by the end of 2025?
3
Resolution / Starting Odds
Decrease by more than 10% • 25%
Remain within ±10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Financial statements and stock market data
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Potentially $400 Million, to Enhance Neuraceq Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings, a diagnostic imaging company based in the U.S., has announced its acquisition of Germany-based Life Molecular Imaging for an upfront payment of $350 million, with potential additional milestones of up to $400 million. This acquisition aims to enhance Lantheus's capabilities in the Alzheimer's disease radiodiagnostic market, particularly through Life Molecular Imaging's Neuraceq, an F-18 PET imaging agent approved for detecting beta-amyloid plaques in patients being evaluated for Alzheimer's. The transaction is part of Lantheus's strategy to accelerate innovation in the growing market for Alzheimer's diagnostics.
View original story
Similar markets
5% to 10% • 25%
Less than 5% • 25%
More than 15% • 25%
11% to 15% • 25%
No • 50%
Yes • 50%
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than $15 billion • 25%
$15 billion to $20 billion • 25%
$20 billion to $25 billion • 25%
More than $25 billion • 25%
Decrease • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
Decrease by 0% to 10% • 25%
Increase by 0% to 10% • 25%
Other • 25%
Remains 20% or more below pre-announcement level • 25%
Recovers to within 10% of pre-announcement level • 25%
Exceeds pre-announcement level • 25%
Decrease by more than 20% • 25%
Decrease by 0-20% • 25%
Increase by 0-20% • 25%
Increase by more than 20% • 25%